{"entity":{"id":"velavigo","kind":"company","name":"VelaVigo","aka":["VelaVigo Bio","橙帆医药"],"tldr":"VelaVigo is a China-based biotechnology company that leads 3 cancer trials in OnCo, testing the bispecific antibody-drug conjugates VBC101, VBC103 and VBC108 in advanced solid tumours.","summary":"VelaVigo is a Shanghai-based biotechnology company founded in 2021 that discovers bispecific and multispecific antibodies, antibody-drug conjugates and other biologic modalities for cancer, autoimmune, neurodegenerative and eye diseases. It has first-in-human trials of the bispecific ADCs VBC101, VBC103, VBC106, VBC108 and VBC117 in the United States, Australia and China. On ClinicalTrials.gov it is the lead sponsor of 3 trials recorded in OnCo: NCT07299747 (phase 1/2, Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors), NCT07136779 (phase 1/2, First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies) and NCT07700160 (phase 1/2, First-in-Human Trial of VBC108 in Participants With Advanced Malignant Solid Tumors). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.velavigo.com"},{"label":"ClinicalTrials.gov: trials led by VelaVigo","url":"https://clinicaltrials.gov/search?lead=VelaVigo%20Bio%20Inc"}],"tags":["ctgov-sponsor"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07299747","nct07136779","nct07700160"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"Shanghai","country":"CN","companyType":"biotech","website":"https://www.velavigo.com","founded":2021,"stage":"startup","investors":[],"funding":[]},"route":"/companies/velavigo/","neighbours":{"trial":[{"id":"nct07299747","kind":"trial","name":"Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors","route":"/trials/nct07299747/"},{"id":"nct07136779","kind":"trial","name":"First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies","route":"/trials/nct07136779/"},{"id":"nct07700160","kind":"trial","name":"First-in-Human Trial of VBC108 in Participants With Advanced Malignant Solid Tumors","route":"/trials/nct07700160/"}]}}